<?xml version='1.0' encoding='utf-8'?>
<document id="26181194"><sentence text="Evaluation of Potential Pharmacokinetic Drug-Drug Interaction between Armodafinil and Aripiprazole in Healthy Adults."><entity charOffset="70-81" id="DDI-PubMed.26181194.s1.e0" text="Armodafinil" /><entity charOffset="86-98" id="DDI-PubMed.26181194.s1.e1" text="Aripiprazole" /><pair ddi="false" e1="DDI-PubMed.26181194.s1.e0" e2="DDI-PubMed.26181194.s1.e0" /><pair ddi="false" e1="DDI-PubMed.26181194.s1.e0" e2="DDI-PubMed.26181194.s1.e1" /></sentence><sentence text="Armodafinil, a moderate inducer of cytochrome P450 (CYP) 3A4, has been studied as adjunctive therapy to maintenance medications for major depressive episodes associated with bipolar I disorder"><entity charOffset="0-11" id="DDI-PubMed.26181194.s2.e0" text="Armodafinil" /></sentence><sentence text=" We evaluated the effect of daily dosing with armodafinil on the pharmacokinetics and safety of the CYP3A4 substrate aripiprazole, an atypical antipsychotic used to treat bipolar I disorder"><entity charOffset="46-57" id="DDI-PubMed.26181194.s3.e0" text="armodafinil" /><entity charOffset="117-129" id="DDI-PubMed.26181194.s3.e1" text="aripiprazole" /><pair ddi="false" e1="DDI-PubMed.26181194.s3.e0" e2="DDI-PubMed.26181194.s3.e0" /><pair ddi="false" e1="DDI-PubMed.26181194.s3.e0" e2="DDI-PubMed.26181194.s3.e1" /></sentence><sentence text="" /><sentence text="Healthy adults received 15 mg aripiprazole alone and after armodafinil (250 mg/day) pretreatment"><entity charOffset="30-42" id="DDI-PubMed.26181194.s5.e0" text="aripiprazole" /><entity charOffset="59-70" id="DDI-PubMed.26181194.s5.e1" text="armodafinil" /><pair ddi="false" e1="DDI-PubMed.26181194.s5.e0" e2="DDI-PubMed.26181194.s5.e0" /><pair ddi="false" e1="DDI-PubMed.26181194.s5.e0" e2="DDI-PubMed.26181194.s5.e1" /></sentence><sentence text=" Pharmacokinetic parameters were derived from plasma concentrations of aripiprazole and its active metabolite, dehydro-aripiprazole, obtained over 16 days after each aripiprazole administration"><entity charOffset="71-83" id="DDI-PubMed.26181194.s6.e0" text="aripiprazole" /><entity charOffset="119-131" id="DDI-PubMed.26181194.s6.e1" text="aripiprazole" /><entity charOffset="166-178" id="DDI-PubMed.26181194.s6.e2" text="aripiprazole" /><pair ddi="false" e1="DDI-PubMed.26181194.s6.e0" e2="DDI-PubMed.26181194.s6.e0" /><pair ddi="false" e1="DDI-PubMed.26181194.s6.e0" e2="DDI-PubMed.26181194.s6.e1" /><pair ddi="false" e1="DDI-PubMed.26181194.s6.e0" e2="DDI-PubMed.26181194.s6.e2" /><pair ddi="false" e1="DDI-PubMed.26181194.s6.e1" e2="DDI-PubMed.26181194.s6.e1" /><pair ddi="false" e1="DDI-PubMed.26181194.s6.e1" e2="DDI-PubMed.26181194.s6.e2" /></sentence><sentence text=" Steady-state pharmacokinetics of armodafinil and its 2 circulating metabolites was assessed"><entity charOffset="34-45" id="DDI-PubMed.26181194.s7.e0" text="armodafinil" /></sentence><sentence text="" /><sentence text="Of 36 subjects enrolled, 24 were evaluable for pharmacokinetic analysis" /><sentence text=" Armodafinil reduced systemic exposure to aripiprazole (Cmax, - 8%; AUC0-∞, -34%) and dehydro-aripiprazole, which is both formed and eliminated in part via CYP3A4 (Cmax, - 10%; AUC0-∞, - 32%)"><entity charOffset="1-12" id="DDI-PubMed.26181194.s10.e0" text="Armodafinil" /><entity charOffset="42-54" id="DDI-PubMed.26181194.s10.e1" text="aripiprazole" /><entity charOffset="94-106" id="DDI-PubMed.26181194.s10.e2" text="aripiprazole" /><pair ddi="false" e1="DDI-PubMed.26181194.s10.e0" e2="DDI-PubMed.26181194.s10.e0" /><pair ddi="false" e1="DDI-PubMed.26181194.s10.e0" e2="DDI-PubMed.26181194.s10.e1" /><pair ddi="false" e1="DDI-PubMed.26181194.s10.e0" e2="DDI-PubMed.26181194.s10.e2" /><pair ddi="false" e1="DDI-PubMed.26181194.s10.e1" e2="DDI-PubMed.26181194.s10.e1" /><pair ddi="false" e1="DDI-PubMed.26181194.s10.e1" e2="DDI-PubMed.26181194.s10.e2" /></sentence><sentence text=" Adverse events were generally consistent with known safety profiles of each agent" /><sentence text="" /><sentence text="Systemic exposure to aripiprazole and dehydro-aripiprazole was moderately reduced following armodafinil pretreatment"><entity charOffset="21-33" id="DDI-PubMed.26181194.s13.e0" text="aripiprazole" /><entity charOffset="46-58" id="DDI-PubMed.26181194.s13.e1" text="aripiprazole" /><entity charOffset="92-103" id="DDI-PubMed.26181194.s13.e2" text="armodafinil" /><pair ddi="false" e1="DDI-PubMed.26181194.s13.e0" e2="DDI-PubMed.26181194.s13.e0" /><pair ddi="false" e1="DDI-PubMed.26181194.s13.e0" e2="DDI-PubMed.26181194.s13.e1" /><pair ddi="false" e1="DDI-PubMed.26181194.s13.e0" e2="DDI-PubMed.26181194.s13.e2" /><pair ddi="false" e1="DDI-PubMed.26181194.s13.e1" e2="DDI-PubMed.26181194.s13.e1" /><pair ddi="false" e1="DDI-PubMed.26181194.s13.e1" e2="DDI-PubMed.26181194.s13.e2" /></sentence><sentence text=" The combination was generally well tolerated under the conditions studied" /><sentence text="" /></document>